Overview

A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Status:
Completed

Trial end date:
2018-07-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Dimethyl Fumarate